Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLXTE-HAase1001
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
HLXTE-HAase1001 is a recombinant human hyaluronidase independently developed by Shanghai Henlius Biotech. It is designed as an enabling co-formulation agent to facilitate the subcutaneous administration of biologics, transforming time-consuming intravenous infusions into rapid subcutaneous injections. By temporarily breaking down hyaluronan in the extracellular matrix, it increases the dispersion and absorption of co-injected drugs, allowing larger volumes to be administered under the skin. In August 2026, Henlius granted Sandoz a non-refundable option for HLXTE-HAase1001 as part of a broader biosimilars collaboration. The asset is currently in process development.
- Other names
- recombinant human hyaluronidase
Beyond the preview
Go deeper on HLXTE-HAase1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLXTE-HAase1001.